|
国际皮肤性病学杂志 2005 31 (5): 291-293 ISSN: 2096-5540 CN: 32-1880/R |
|
|
|
|
|
自身免疫病的生物学治疗进展 |
温丽虹, 郑敏 |
浙江大学医学院附属第二医院皮肤科, 杭州310009 |
收稿日期 2005-02-21 修回日期 null 网络版发布日期 null |
参考文献 [1] Horwitz DA, Zheng SG, Gray JD, et al. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease.Semin Immunol, 2004, 16:135-143. [2] Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes. Immunol Today, 1994, 15:450-454. [3] Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.Rheumatology (Oxford), 2001, 40:205-211. [4] Cambridge G, Leandro MJ, Edwards JCW, et al. B lymphocyte depletion in patients with rheumatoid arthritis:serial studies of immunological parameters. Arthritis Rheum, 2002, 46(Suppl 9):S1350. [5] Stahl HD, Szczepanski L, Szechinski J, et al. Rituximab in RA:efficacy and safety from a randomized controlled trial. Ann Rheum Dis,2003,62(Suppl 1):OP004. [6] Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody:a randomized,placebo-controlled trial in patients with rheumatoid arthritis. Arthritis Rheum, 2002, 46(Suppl 9):S446. [7] Rathmell JC, Fournier S, Weintraub BC, et al. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4+ T cells. J Exp Med, 1998, 188:651-659. [8] Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRⅢa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum,2003, 48(2):455-459. [9] Leandro M J, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum, 2002, 46:2673-2677. [10] Anolik JH, Campbell D, Felgar RE, et al. B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum,2002, 46(Suppl 9):S717. [11] Tokano Y, Morimoto S, Kaneko H,et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines. Clin Exp Immunol, 1999, 116:169-173. [12] Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. Pharmacol Rev, 2003, 55:241-269. [13] Aringer M, Stummvoll GH, Steiner G,et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford),2001, 40:876-881. [14] Aringer M, Zimmermann C, Graninger WB, et al. TNF is an essential mediator in lupus nephritis. Arthritis Rheum, 2002, 46:3418. [15] Su X, Zhou T, Yang P, et al. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.Arthritis Rheum, 1998, 41:139-149. [16] Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus:a rationale for therapeutic intervention. Lupus, 2004, 13:344-347. [17] Kiberd BA, Stadnyk AW. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology, 1995, 30:131. [18] Herrera-Esparza R,Barbosa-Cisneros O,Villalobos-Hurtado R,et al.Renal Expression of Il-6 and TNFα genes in lupus nephritis. Lupus,1998, 7:154-158. [19] Bossu P, Neumann D, Del Giudice E,et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.Proc Natl Acad Sci U S A, 2003, 100:14181-14186. |
|
|
|
通讯作者: 郑敏,E-mail:minz@zju.edu.cn |
|